Multiple sclerosis (MS) is the commonest non‐traumatic disabling disease to affect young
adults. The incidence of MS is increasing worldwide, together with the socioeconomic …

Background Treatment of multiple sclerosis with natalizumab is complicated by rare
occurrence of progressive multifocal leukoencephalopathy (PML). Between July, 2006, and …

Objective: To evaluate the association between diagnosis of Parkinson disease (PD) and
risk factors or early symptoms amenable to population‐based screening. Methods: A …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Background Natalizumab is the first α4 integrin antagonist in a new class of selective
adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of …

Initially thought to play a restricted role in calcium homeostasis, the pleiotropic actions of
vitamin D in biology and their clinical significance are only now becoming apparent …

Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …

This study identifies by microautoradiography activated microglia/macrophages as the main
cell type expressing the peripheral benzodiazepine binding site (PBBS) at sites of active …

Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …